In April 2021, the high-tech and innovative pharmaceutical company Omini Pharma (OMNI) announced a final merger agreement with the medical promotion company Shanghai Sinomedcare Co., Ltd. (SMC).
As the legal counsel of SMC, Llinks provided professional legal services such as proposal demonstration, drafting of transaction documents, and negotiation for this project with its rich project experience in the field.
Founded in 2011, OMNI is a high-tech innovative pharmaceutical company focusing on drug delivery technologies. The company is dedicated to the research and development, and industrialization of inhalation formulations, with a level of expertise comparable to that of top pharmaceutical companies in Europe and America. At present, the company has the capability of independent R&D and manufacturing of metered dose inhaler, dry powder inhaler, inhaled nebulizing solutions and nasal spray, and has a proprietary design platform incorporating breathing apparatus. The project is gradually entering phase III clinical trials, which will bring China's self-developed international-level respiratory preparations to the domestic market.
SMC was established in 2011, focusing on the marketing and academic promotion of products in the respiratory and pediatric fields, has excellent brand building capabilities, has a strong network of experts and doctors and a professional elite marketing team, and has a rich market Access experience, covering most hospitals, retail pharmacies, and e-commerce platforms, and having an independent innovative SSaaS platform to expand digital, innovative and efficient business promotion models.
